Next Phase Newsletter

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI March registration is now open! The Redefining Early Stage Investments (RESI) 2022 conference series continues March 22-24 in a virtual format. RESI is a partnering conference that is dedicated to connecting early-stage founders in life science and healthcare with capital, licensing, and strategic partnerships that are a fit for their product and stage of development.

The RESI partnering platform enables attendees to filter through hundreds of investors, service providers, and technology assets to find the best fit for their needs. Additionally, RESI organizes expert panels and educational workshops to provide insights into the industry and teach skills to help entrepreneurs fundraise successfully. RESI is also unique in its Innovator’s Pitch Challenge, which provides a platform for fundraising founders to pitch directly to a panel of active investors in their sector applications are open!

RESI is a one-stop-shop for all buyers and sellers in the early-stage arena. Startups looking to partner with 350+ investors can save $300 when they register for Digital RESI March by January 28. Learn more about offerings for investors and service providers and reach out to see how RESI can help in your fundraising journey!

By Rory McCann, Marketing Manager & Conference Producer, LSN

Only a few days into the new year and already one of the biggest fundraising events of the year is starting. Digital RESI JPM, January 11-13 partnering is open and vibrant with hundreds of attendees taking advantage of the opportunities available to fundraising entrepreneurs in 2022. There is still time to sign up for early-stage companies seeking capital, licensing, and strategic partnerships, but even more importantly is the yearlong ecosystem of partnering that companies at all stops along their early-stage journey can take advantage of.

If 2022 is your year to kick your fundraising into high gear, check out the Digital RESI JPM agenda, as well as the plethora of events and services available to help you meet your goals and be successful in the new year.

	Tuesday (1/11)	Wednesday (1/12)	Thursday (1/13)
10AM EST	Innovator’s Pitch Challenge #1 Devices & Diagnostics	Family Offices Panel	Innovator’s Pitch Challenge #8 Longevity-Devices & Digital Health
		Innovator’s Pitch Challenge #5 Oncology Therapeutics & AI Drug Discovery Applications
11AM EST	Medical Devices Investor Panel	Defining and Funding Age-Tech Innovations Panel	Diagnostics Investor Panel
12PM EST	Negotiating Term Sheets	Licensing in Life Sciences	How to Evaluate Your Banking Partner Workshop
1PM EST	Innovator’s Pitch Challenge #2 Therapeutics	Innovator’s Pitch Challenge #6 Diagnostics & Digital Health	Innovator’s Pitch Challenge #9 Devices and R&D Services
		Fundraising Challenges and Highlights of First-Time Founders & CEOs
2PM EST	The Regulatory Pathway for AI in Healthcare Panel	Digital Health Investor Panel	Emerging Products and Technologies for Aging at Home Panel
3PM EST	Big Pharma Panel	The Early Stage Pivot Panel	Corporate VC Panel
	Innovator’s Pitch Challenge #3 Oncology Diagnostics		Innovator’s Pitch Challenge #10 Medical Devices
4PM EST	Tales from the Road: Age-Tech Innovators on their Fundraising Journey	Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey	Tales from the Road: AI Innovators on their Fundraising Journey
5PM EST	Innovator’s Pitch Challenge #4 AI-Devices & Digital Health	Innovator’s Pitch Challenge #7 Therapeutics	Innovator’s Pitch Challenge #11 Oncology Therapeutics
	Longevity Investors Share Their Investment Thesis	Longevity Entrepreneurs Discuss Their New Products

• Digital RESI Conference Series and Innovator’s Pitch Challenge
• Digital RESI Sponsorship
• Life Science Nation Investor Database (Get a free demo today!)
• Life Science Nation BD Database (Get a free demo today!)
• Life Science Nation Branding & Messaging

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s first and largest event of the year, Digital RESI JPM 2022, is coming up in less than a week. With most of the major events happening around JPM going virtual, LSN has been overwhelmed by the number of registration requests that we have been receiving, as we do our best to ensure that every investor is a direct, active investor who looks at the early-stage life science and healthcare space. With 300+ investors confirmed to attend, including large pharma/medtech, family offices, corporate venture capitals funds, and more, this digital conference is a great opportunity to kick off your fundraising campaign and start a dialog with potential investors and strategic partners in 2022. Register now to meet with these investors:

The firm is the corporate venture arm of a senior living communities with in multiple locations and a seniors members club . The firm invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm is a strategic and active investor, and will generally take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.